3rd ESTRO Forum 2015 all leaves was considered satisfactory. This condition was fulfilled by 36 of 44 participants. Follow-up of unsatisfactory results is on-going.
Purpose/Objective: With regard to the complex dose distributions produced by active raster scanning, each treatment plan has to be verified before treatment. At the Heidelberg Ion-beam Therapy Center (HIT) patient specific dose verification is currently performed by using an array of 24 ionization chambers. Due to the limited sampling period (~14 mm) of this system, a high resolution (~0.2 mm) flat panel detector has been investigated to supplement these dose measurements with fluence measurements in the dose plateau area of the depth dose distributions. Materials and Methods: A procedure is presented to correct the flat panel raw data and convert the corrected data into fluence distributions after suitable energy calibration. In the present work the fluence measurements have been realized using patient relevant accelerator settings. Additionally, a state of the art flat panel detector (XRD 0822 without scintillator, Perkin Elmer, Germany) was investigated with respect to signal quality and mandatory image corrections. After each measurement, the generated fluence distributions are checked against expected fluence distributions calculated from respective beam parameters. Using this method, fluence distributions can additionally be checked for each iso energy layer. To quantify the agreement between the measured and calculated fluence distributions a gamma index analysis has been performed. A global gamma index criterion of 5 % fluence deviation and 1 mm distance to agreement was used. Values below 3 % of the fluence maximum in each iso energy layer have not been taken into account. Results: Treatment plans with up to 2-3 Gy can be measured at the highest available beam intensity without any effects of detector signal saturation. So far, 6 proton treatment plans and 12 carbon ion treatment plans have been investigated. Averaged over all treatment plans, the gamma-index criterion was met in more than 98 % of the fluence values for protons and more than 96 % for carbon ions. Conclusions: A specific protocol was established to process flat panel raw data: It contains necessary offset, gain and bad pixel corrections, as well as an energy calibration. Based on two-dimensional high resolution fluence measurements in the dose plateau area of the depth dose distributions it is possible to provide supplementary information to conventional dose measurements. The corrected and calibrated flat panel detector signal shows promising results compared to the calculated data. However, before using this protocol in clinical routine, further studies, especially towards irradiation damage of the detector, have to be performed. So far, further bad pixels have not been detected.
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Flattening filter free beam used for normal fractionated treatments H.R. Jensen 1 , A. Bertelsen 1 , C. Brink 1 , J. Barber 2 , D. Thwaites 3 , C.R. Hansen 3 1 Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark 2 Department of Radiation Oncology, Nepean Cancer Care Center, Sydney, Australia 3 Institute of Medical Physics, University of Sydney, Sydney, Australia Purpose/Objective: Flattening Filter Free (FFF) radiotherapy has recently become widely discussed in particular for stereotactic treatments where large doses per fraction (frac.) can be delivered quicker due to the higher dose rate. However, the original idea of FFF was not mainly to increased dose rate, but instead to reduce head scatter and thereby scattered dose to the entire patient. The purpose of this study was to investigate if normal fractionated treatments (1.8 -2.0 Gy per frac.) could be delivered with clinically relevant dose accuracy and if there were any gains in treatment delivery because of the higher dose rate, or gains in treatment plans from the reduced scatter. Materials and Methods: In three of the main radiotherapy treatment sites (brain, head and neck (H&N) and lung) the first 10 curatively treated patients in 2014, having a single target and treated with a single full or half VMAT arc were selected. The patients were re-planned on Pinnacle ver. 9.8 for the Elekta Versa HD linac. The dose prescriptions were 59.4 Gy in 33 frac. for brain and 66 Gy in 33 frac. for H&N and lung. For each patient two plans were created with different beams (6 MV and 6 MV FFF). Both plans were optimised with the same fixed number of iterations and with no change to VMAT objectives. All treatment plans were delivered and dose accuracy evaluated using the Sun Nuclear ArcCheck phantom and analysed using a 3% and 3 mm global gamma between planned and measured doses. Beam on times were recorded for treatment beams. All DVH metrics were tested for significant differences with a paired two-sided Wilcoxon-signed rank test, with a significance level of 5%. Results: The mean dose to the body is reduced in the FFF treatment plans compared to the FF (Flattening Filter) plans for all 3 treatments sites (p=0.05, see table). For brain and H&N there are only small differences in target dose, however for the lung treatment PTV D 2% (near max) and D 98% (near minimum) the FFF plans are slightly less favourable. For H&N the FFF delivery is slower to deliver despite the higher dose rate. This might be due to the higher MLC modulation needed to compensate for the inhomogeneous profile of the FFF beam. The higher MLC modulation effect is seen for all three sites in the number of MU needed for the plans (p=0.002). The pass rate from the ArcCheck measurements are all clinically acceptable, however the H&N FFF plans have lower pass rates. This can be related to the MLC modulation needed to compensate for the inhomogeneous beam profile using FFF for larger targets. Same trend is seen for the lung treatments, where there is a range of target sizes.
Conclusions:
Clinically acceptable FFF treatment plans can be created and delivered for normally fractionated treatments in all three anatomical sites. The reduced head scatter from removing the flattening filter produces reduced total body dose, which could be clinically relevant to the aim of reducing secondary cancers. Purpose/Objective: Evaluation of the characteristics of the new EPID PV-aS1200 by Varian for its dosimetric usage with the GLAaS algorithm, where a dedicate configuration phase allows to convert the EPID reading into absorbed dose to water.
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Materials and Methods:
The new PV-aS1200 imager has an active area of a 40x40cm 2 (1190x1190 pixel), with a backscatter shielding included in the new cassette engineering. Its intrinsic characteristics were investigated on an Edge accelerator equipped with 6X, 6FFF, 10FFF beams. For the same energies, data were also compared to PV-aS1000 acquisitions from a TrueBeam.
A first level of investigations covered signal linearity with dose, response to primary and transmitted radiation, saturation relative to dose and dose rate, arm backscatter as a function of field size, ghosting. After that first detector assessment, the robustness of the GLAaS dose calibration process was evaluated in terms of absolute absorbed dose, relative output factors and profile parameters. Finally, GLAaS was validated for aS1200 as pre-treatment QA tool for RapidArc plans, covering different dose/fraction prescriptions. The mutual position of the detector and the linac head was measured in a cine mode during full rotations. Results: For all energies, aS1200 readings showed an optimal linearity relative to MU (R 2 =1.00), with a residual deviation less than 0.5% for more than 3MU. The detector response to primary and transmitted radiation was modelled and showed to be similar to the aS100 detector. The aS1200 confirmed to have no saturation for measurements at isocenter and the maximum dose rate (1400 and 2400 MU/min for 6 and 10FFF respectively). The arm backscatter variation with field size is now compensated with the new engineering. Consequently the dose calibration according to the GLAaS model was successfully implemented, allowing QA for all beams with no limitations of field size or dose rate. Comparison between measured dose map and TPS calculated dose in water was assessed through the Gamma Agreement Index GAI, for different DTA and ΔD criteria, resulting in GAI > 95% (2%, 2mm criteria).
Conclusions:
The new aS1200 detector improved the performance of the previous aS1000, with no more limitation in terms of field size and/or dose rate. The effective resolution of arm backscatter allows a more robust usage of the new detector. The usability for pre-treatment QA for RapidArc cases is confirmed in all conditions, from stereotactic to very large volumes, from common to very high dose rates.
Poster: Physics track: Treatment planning calculation, optimisation
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Pareto front investigation of TomoTherapyís plan quality range G. De Kerf 1 , D. Van Gestel 2 , L. Mommaerts 2 , D. Van den Weyngaert 2 , D. Verellen 3 1 GZA St Augustinus Iridium Kankernetwerk, Radiotherapy, Wilrijk, Belgium 2 ZNA, Radiotherapy, Antwerpen, Belgium 3 UZ Brussel, Radiotherapy, Brussel, Belgium Purpose/Objective: By creating Pareto fronts for Helical TomoTherapy (HT) plans, the influence of field width (FW), modulation factor (MF) and pitch on the plan quality can be investigated and Pareto optimal combinations can be deduced. Materials and Methods: For every oropharyngeal cancer patient out of five, 90 TomoEdge plans were made (each with a unique combination of MF and pitch) [1-2]. The homogeneity index (HI), conformity index (CI), D near-max (D2) and D near-min (D98) of the PTVs were plotted in a Pareto front
